胰腺癌患者血浆中KRAS突变的研究  

Plasma-based KRAS mutation analysis in patients with pancreatic cancer

作　　者：刘佩佳[1] 任蕾[1] 刘佩芳[1] 闫永毅[1] 邢雪君 梁红艳[1] 姜晓峰[1] LIU Pei-jia;REN Lei;LIU Pei-fang;YAN Yong-yi;XING Xue-jun;LIANG Hong-yan;JIANG Xiao-feng(Department of Clinical Laboratory,The Second Affiliated Hospital of Harbin Medical Universi-ty,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院检验科,黑龙江哈尔滨150081

出　　处：《哈尔滨医科大学学报》2018年第2期153-155,共3页Journal of Harbin Medical University

摘　　要：目的探讨胰腺癌血浆是否可以替代组织样本进行突变分析。方法收集54例胰腺癌患者的血浆及组织样本,分别提取血浆及组织的DNA。将组织DNA经COLD-PCR扩增后进行测序分析,明确每一例样本的突变状态。血浆DNA经巢式COLD-PCR/Taq Man-MGB探针进行检测。将每一例血浆样本KRAS突变状态与相对应组织样本比较。结果经测序54例组织中有49例(90. 7%)存在KRAS突变,其中有24例(44. 4%)为密码子12(GGT> GAT)突变;血浆中有27例(50. 0%)存在KRAS密码子12(GGT> GAT)突变,其中21例在配对组织中检出该位点突变。统计分析发现血浆中KRAS密码子12(GGT> GAT)突变和组织中该点突变具有高度相关性(相关系数K=0. 667; P <0. 001)。结论胰腺癌患者血浆可以替代组织进行突变分析。Objective To investigate whether plasma is able to be used for mutation analysis instead of tissue samples. Methods Plasma and matched tumor tissues from 54 patients with pancreatic cancer before treatment were collected, DNA extracted were obtained. Mutations of the tissue specimens in KRAS was amplified and sequenced by COLD-PCR. Plasma KRAS gene mutation on codon 12（GGT 〉 GAT） was detected using a nested COLD-PCR/TaqMan- MGB probe. Mutations in plasma and matched tumors were compared. Results KRAS muta- tion on codon 12（GGT 〉 GAT） was found in 27（50.0% ） plasma specimens and 24（44.4% ） in matched tumor tissues. KRAS mutation on codon 12（GGT 〉 GAT） was found in 21 speci- mens in plasma and matched tissues, which showed a high correlation between the mutations found in plasma DNA and the mutations found in the corresponding tumor DNA （P 〈 0. 001 ; correlation index, K = 0. 667）. Conclusion Plasma DNA may be used as a potential sample for KRAS mutation analysis in pancreatic cancer.

关 键 词：胰腺癌 COLD—PCR 血浆DNA 

分 类 号：R735.9[医药卫生—肿瘤]